Journal
SCIENCE
Volume 363, Issue 6432, Pages 1175-1181Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaw4153
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA204915] Funding Source: Medline
Ask authors/readers for more resources
Cancer treatment decisions are increasingly based on the genomic profile of the patient's tumor, a strategy called precision oncology. Over the past few years, a growing number of clinical trials and case reports have provided evidence that precision oncology is an effective approach for at least some children with cancer. Here, we review key factors influencing pediatric drug development in the era of precision oncology. We describe an emerging regulatory framework that is accelerating the pace of clinical trials in children as well as design challenges that are specific to trials that involve young cancer patients. Last, we discuss new drug development approaches for pediatric cancers whose growth relies on proteins that are difficult to target therapeutically, such as transcription factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available